All In Biotech

Drug Trial Radar · NCT06632951

Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC)

A Phase 2, Open-Label, Randomized Study of Livmoniplimab in Combination With Budigalimab Versus Chemotherapy in Subjects With Metastatic Urothelial Carcinoma

Last checked: Nov 20, 2026Latest source record: Aug 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 150 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

150

Planned (sponsor's estimate)

Start

Jan 20, 2025

Primary completion

Mar 2027

Study completion Aug 2028

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Oct 9, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Urothelial carcinoma (UC) is the ninth most common cancer type worldwide. While the treatment of front-line metastatic urothelial carcinoma (mUC) has improved, there remains a high unmet need for effective therapies for participants who have recurrent disease and disease that has progressed after frontline treatment. The purpose of this study is to evaluate the optimized dose, adverse events, and efficacy of livmoniplimab in combination with budigalimab. Livmoniplimab is an investigational drug being developed for the treatment of mUC. There are 3 treatment arms in this study and participants will be randomized in a 1:1:1 ratio. Participants will either receive livmoniplimab (at one of 2 different doses) in combination with budigalimab (another investigational drug), or either docetaxel, paclitaxel, or gemcitabine (based on investigator's choice). Approximately 150 adult participants will be enrolled in the study across 56 sites worldwide. In arm 1, participants will receive intravenously (IV) infused livmoniplimab (dose A) in combination with IV infused budigalimab. In arm 2, participants will receive IV infused livmoniplimab (dose B) in combination with IV infused budigalimab. In arm 3 (control), participants will receive the investigator's choice: IV infused or injected docetaxel; IV infused or injected paclitaxel; or IV infused gemcitabine. The estimated duration of the study is up to approximately 3.5 years. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and may require frequent medical assessments, blood tests, questionnaires, and scans.

Conditions

  • Urothelial Carcinoma

Interventions

  • LivmoniplimabDrug

    Intravenous (IV) Infusion

  • BudigalimabDrug

    IV Infusion

  • DocetaxelDrug

    IV Infusion

  • PaclitaxelDrug

    IV Injection

  • DocetaxelDrug

    IV Injection

  • PaclitaxelDrug

    IV Infusion

  • GemcitabineDrug

    IV Infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival (OS)Time frame: Up to Approximately 3.5 Years

Locations

37 sites in 8 countries. Site status is shown where the registry gives one.

  • Highlands Oncology Group - Springdale /ID# 270290

    Springdale, Arkansas

  • University of California San Francisco - Mission Bay /ID# 270289

    San Francisco, California

  • Yale University School of Medicine /ID# 270449

    New Haven, Connecticut

  • Medical Oncology Hematology Consultants /ID# 271347

    Newark, Delaware

  • Florida Cancer Specialists - North /ID# 271215

    St. Petersburg, Florida

  • Icahn School of Medicine at Mount Sinai /ID# 270272

    New York, New York

  • University Hospitals Cleveland Medical Center /ID# 271010

    Cleveland, Ohio

  • The Ohio State University /ID# 271349

    Columbus, Ohio

  • SCRI Oncology Partners /ID# 270439

    Nashville, Tennessee

  • Texas Oncology - Austin Central /ID# 271284

    Austin, Texas

  • Utah Cancer Specialist /ID# 270810

    Salt Lake City, Utah

  • Centre Hospitalier Affilié Universitaire de Québec - Hôpital de l'Enfant-Jésus /ID# 271635

    Québec, Quebec, Canada

  • Institut Paoli-Calmettes /ID# 270580

    Marseille, Bouches-du-Rhone, France

  • Hôpital Foch /ID# 270573

    Suresnes, Hauts-de-Seine, France

  • Institut Gustave Roussy /ID# 270575

    Villejuif, Île-de-France Region, France

  • Rambam Health Care Campus /ID# 270105

    Haifa, Israel

  • Rabin Medical Center /ID# 270107

    Petah Tikva, Israel

  • Meir Medical Center /ID# 270108

    Kfar Saba, Central District, Israel

  • The Chaim Sheba Medical Center /ID# 270096

    Ramat Gan, Tel Aviv, Israel

  • Tel Aviv Sourasky Medical Center /ID# 270106

    Tel Aviv, Tel Aviv, Israel

  • Hirosaki University Hospital /ID# 270531

    Hirosaki, Aomori, Japan

  • Fukushima Medical University Hospital /ID# 270752

    Fukushima, Fukushima, Japan

  • University of Tsukuba Hospital /ID# 270354

    Tsukuba, Ibaraki, Japan

  • Kanazawa University Hospital /ID# 270473

    Kanazawa, Ishikawa-ken, Japan

  • Aidport Sp. z o.o. /ID# 270049

    Skórzewo, Greater Poland Voivodeship, Poland

  • Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie Panstwowy Instytut Bada /ID# 270046

    Warsaw, Masovian Voivodeship, Poland

  • National Cancer Center /ID# 270453

    Goyang-si, Gyeonggido, South Korea

  • Chonnam National University Hwasun Hospital /ID# 271299

    Hwasun-gun, Jeonranamdo, South Korea

  • Yonsei University Health System Severance Hospital /ID# 270317

    Seoul, Seoul Teugbyeolsi, South Korea

  • Asan Medical Center /ID# 270898

    Seoul, Seoul Teugbyeolsi, South Korea

  • Samsung Medical Center /ID# 270318

    Seoul, Seoul Teugbyeolsi, South Korea

  • Parc de Salut Mar - Hospital del Mar /ID# 270173

    Barcelona, Spain

  • Hospital Universitario Vall d'Hebron /ID# 269783

    Barcelona, Spain

  • Hospital Clinic de Barcelona /ID# 269789

    Barcelona, Spain

  • Hospital MD Anderson Cancer Center Madrid /ID# 269780

    Madrid, Spain

  • Hospital Clinico San Carlos /ID# 269786

    Madrid, Spain

  • Hospital Universitario Virgen del Rocio /ID# 269782

    Seville, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.